Company Overview: Cynata Therapeutics

Industry News

6 Sep

Cynata and FUJIFILM Sign Non-binding Development and Commercialisation Term Sheet

NEW YORK, Sept. 5, 2016 /PRNewswire/ — Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (CYP.AX), announced the execution of a term sheet with FUJIFILM Corporation of Japan for the development and commercialisation of certain Cynata technology, including Cynata’s lead induced pluripotent stem cell (iPSC) derived therapeutic...

Read more

21 Jun

Cynata Prepares for Phase 1 Clinical Trial

Melbourne, Australia; 21 June 2016: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced that it intends to file an application for regulatory approval with the UK Medicines and Healthcare products Regulatory Agency (MHRA) for a Phase 1 clinical trial of CYP-001 in July 2016. Cynata’s...

Read more

9 May

Cynata Enters License Option Agreement with apceth GmbH & Co. KG

– apceth to develop Cynata’s Cymerus™ mesenchymal stem cells (MSCs) engineered with apceth’s proprietary genetic modification technology – Therapeutic targets include cancer and several other devastating diseases – Upfront and milestone payments potentially exceed A$40m in addition to royalty payments – Commercial development of Cymerus™ to be investigated by...

Read more

2 Dec

Cynata Enters Letter of Intent for Strategic Alliance in Japan

Melbourne, Australia and Tokyo, Japan; 3 December 2015: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced today that it has signed a Letter of Intent (LOI) regarding a future strategic alliance with Regience K.K. for Japan and certain other Asian countries. Cynata and Regience...

Read more

19 Oct

StockNewsNow.com Publishes New SNNLive Video Interview With Cynata Therapeutics Ltd.

LOS ANGELES, CA–(Marketwired – October 19, 2015) – StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Dr. Ross Macdonald, Managing Director and CEO of Cynata Therapeutics Ltd. (CYP.AX), is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology,...

Read more

15 Oct

Cynata Therapeutics’ Ross Macdonald Interviewed by The Life Sciences Report

SAN FRANCISCO, CA–(Marketwired – October 15, 2015) – Stem cell therapies have been slowed by high production costs, batch-to-batch variability and limited seed material. Ross Macdonald, CEO of Cynata Therapeutics Ltd.  (CYP.AX), tells The Life Sciences Report how Cynata Therapeutics’ innovative manufacturing methods can generate robust, consistent and inexpensive stem cells, and how...

Read more

14 Oct

Cynata to Investigate Cell Therapy for Cancer in Major New Collaboration

• Collaboration with Dr Khalid Shah of Massachusetts General Hospital/Harvard Medical School • Process involves modifying stem cells to target cancer, building on other clinical uses of unmodified stem cells • Cell therapy for cancer is a rapidly expanding area Melbourne, Australia; 14 October 2015: Stem cell and regenerative...

Read more

Page 1 of 212

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address